Podocytes of AT2 receptor knockout mice are protected from angiotensin II-mediated RAGE induction

American Journal of Nephrology

Volumn 34, Issue 4, 2011, Pages 309-317

  Rüster, Christiane ^a   Franke, Sybille ^a   Wenzel, Ulrich ^b   Schmidthaupt, Robin ^c   Fraune, Christoph ^c   Krebs, Christian ^c   Wolf, Gunter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Advanced glycation end products; Angiotensin II; AT2 receptor; Inflammation; Kidney; Podocytes; RAGE

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; GENE INACTIVATION; GLOMERULUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; WILD TYPE;

ALBUMINURIA; ANGIOTENSIN II; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CROSSES, GENETIC; DIABETIC NEPHROPATHIES; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; MALE; MICE; MICE, INBRED C57BL; PODOCYTES; RECEPTORS, ANGIOTENSIN; RECEPTORS, IMMUNOLOGIC;

EID: 80051585719     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000329321     Document Type: Article

References (33)

1. Rüster C, Wolf G: Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17:2985-2991. (Pubitemid 44707758)
2. Wolf G, Butzmann U, Wenzel UO: The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003;93:P3-P13.
3. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799-812. (Pubitemid 41623305)
4. Schmidt AM, Yan SD, Wautier JL, Stern D: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-497. (Pubitemid 29138585)
5. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-1137. (Pubitemid 36350658)
6. Guo J, Ananthakrishnan R, Qu W, Lu Y, Reiniger N, Zeng S, Ma W, Rosario R, Yan SF, Ramasamy R, D'Agati V, Schmidt AM: RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 2008;19:961-972.
7. Berbaum K, Shanmugam K, Stuchbury G, Wiede F, Körner H, Münch G: Induction of novel cytokines and chemokines by advanced glycation end products determined with a cytometric bead array. Cytokine 2008,41:198-203.
8. Rüster C, Bondeva T, Franke S, Tanaka N, Yamamoto H, Wolf G: Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am J Nephrol 2009;29: 538-550.
9. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK: Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995;377:744-747.
10. Benndorf RA, Krebs C, Hirsch-Hoffmann B, Schwedhelm E, Cieslar G, Schmidt-Haupt R, Steinmetz OM, Meyer-Schwesinger C, Thaiss F, Haddad M, Fehr S, Heilmann A, Helmchen U, Hein L, Ehmke H, Stahl RA, Böger RH, Wenzel UO: Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. Kidney Int 2009;75:1039-1049.
11. Kirchhoff F, Krebs C, Abdulhag UN, Meyer- Schwesinger C, Maas R, Helmchen U, Hilgers KF, Wolf G, Stahl RA, Wenzel U: Rapid development of severe end-organ damage in C57BL/6 mice by combining DOCA salt and angiotensin II. Kidney Int 2008;73:643-650. (Pubitemid 351265325)
12. Rao S, Verkman AS: Analysis of organ physiology in transgenic mice. Am J Physiol Cell Physiol 2000;279:C1-C18. (Pubitemid 30616616)
13. Busch M, Franke S, Wolf G, Rohde RD, Stein G, Collaborative Study Group: The advanced glycation end product Nε-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis 2006;48:571-579. (Pubitemid 44425379)
14. Navarro JF, Milena FJ, Mora C, León C, Garcia J: Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int Suppl 2005;99:S98-S102.
15. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κ B, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-25790.
16. Fujita M, Okuda H, Tsukamoto O, Asano Y, Hirata YL, Kim J, Miyatsuka T, Takashima S, Minamino T, Tomoike H, Kitakaze M: Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:e138-e142. (Pubitemid 44465705)
17. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H: Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 2005;57:4265-4270. (Pubitemid 41116350)
18. Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H: RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular-weight heparin. Diabetes 2006, 55:2510-2522. (Pubitemid 44871151)
19. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-268. (Pubitemid 32656250)
20. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: The expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease. J Am Soc Nephrol 2000;11:1656-1666.
21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462. (Pubitemid 23335891)
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
23. Liebau MC, Lang D, Böhm J, Endlich N, Bek MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstädt H, Fischer KG: Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006;290:F710-F719. (Pubitemid 43724974)
24. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ.: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004;65:30-39. (Pubitemid 38037489)
25. Yoo TH, Li JJ, Kim JJ, Jung DS, Kwak SJ, Ryu DR, Choi HY, Kim JS, Kim HJ, Han SH, Lee JE, Han DS, Kang SW.: Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007;71:1019-1027. (Pubitemid 46741993)
26. Langham RG, Kelly DJ, Cox AJ, Gow RM, Holthofer H, Gilbert RE.: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002;45:1572-1576. (Pubitemid 35352051)
27. Misfud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, Gilbert RE: Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001;44:878-882. (Pubitemid 32642461)
28. Wang L, Flannery PJ, Spurney RF: Characterization of angiotensin II receptor subtypes in podocytes. J Lab Clin Med 2003;142:313-321. (Pubitemid 37487401)
29. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner G, Helmchen U, Stahl RA: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997;100:1047-1058. (Pubitemid 27386288)
30. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F: Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 receptors. Kidney Int 2002;61:1986-1995. (Pubitemid 34539316)
31. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51.
32. Thomas MC, Tikellis C, Burns WM: Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976-2984. (Pubitemid 44743495)
33. Sourris KC, Morley AL, Koitka A, Samuel P, Coughlan MT, Penfold SA, Thomas MC, Bierhaus A, Nawroth PP, Yamamoto H, Allen TJ, Walther T, Hussain T, Cooper ME, Forbes JM: Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 receptors. Diabetologia 2010;53:2442-2451.